Inhibiting RRM2 to enhance the anticancer activity of chemotherapy

被引：95

作者：

Zhan, Yaqiong ^{[1
]}

Jiang, Lushun ^{[1
]}

Jin, Xuehang ^{[1
]}

Ying, Shuaibing ^{[1
]}

Wu, Zhe ^{[1
]}

Wang, Li ^{[2
]}

Yu, Wei ^{[1
]}

Tong, Jiepeng ^{[1
]}

Zhang, Li ^{[1
]}

Lou, Yan ^{[1
]}

Qiu, Yunqing ^{[1
]}

机构：

[1] Zhejiang Univ, Coll Med,State Key Lab Diag & Treatment Infect Di, Affiliated Hosp 1,Collaborat Innovat Ctr Diag & T, Natl Clin Res Ctr Infect Dis,Zhejiang Prov Key La, 79 QingChun Rd, Hangzhou 310000, Zhejiang, Peoples R China

[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Rehabil Med, 79 QingChun Rd, Hangzhou 310000, Zhejiang, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2021年 / 133卷

基金：

中国国家自然科学基金;

关键词：

Ribonucleotide reductase subunit M2; Chemotherapy; Chemoresistance; Small interfering RNA; RRM2; inhibitors; Kinase inhibitors; RIBONUCLEOTIDE REDUCTASE M2; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP; ANTISENSE OLIGONUCLEOTIDE GTI-2040; MESSENGER-RNA EXPRESSION; BREAST-CANCER CELLS; PHASE-I TRIAL; NF-KAPPA-B; PANCREATIC-CANCER; DNA-DAMAGE; SUBUNIT M2;

D O I：

10.1016/j.biopha.2020.110996

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

RRM2, the small subunit of ribonucleotide reductase, is identified as a tumor promotor and therapeutic target. It is common to see the overexpression of RRM2 in chemo-resistant cancer cells and patients. RRM2 mediates the resistance of many chemotherapeutic drugs and could become the predictor for chemosensitivity and prognosis. Therefore, inhibition of RRM2 may be an effective means to enhance the anticancer activity of chemotherapy. This review tries to discuss the mechanisms of RRM2 overexpression and the role of RRM2 in resistance to chemotherapy. Additionally, we compile the studies on small interfering RNA targets RRM2, RRM2 inhibitors, kinase inhibitors, and other ways that could overcome the resistance of chemotherapy or exert synergistic anticancer activity with chemotherapy through the expression inhibition or the enzyme inactivation of RRM2.

引用

页数：8

共 97 条

[31] Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia [J].

Klisovic, Rebecca B. ;

Blum, William ;

Liu, Zhongfa ;

Xie, Zhiliang ;

Kefauver, Cheryl ;

Huynh, Lenguyen ;

Zwiebel, James A. ;

Devine, Steven M. ;

Byrd, John C. ;

Grever, Michael R. ;

Chan, Kenneth K. ;

Marcucci, Guido .

LEUKEMIA & LYMPHOMA, 2014, 55 (06) :1332-1336

[32] Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study [J].

Kunos, Charles ;

Radivoyevitch, Tomas ;

Abdul-Karim, Fadi W. ;

Fanning, James ;

Abulafia, Ovadia ;

Bonebrake, Albert J. ;

Usha, Lydia .

JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10

[33] Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers [J].

Kunos, Charles A. ;

Radivoyevitch, Tomas ;

Waggoner, Steven ;

Debernardo, Robert ;

Zanotti, Kristine ;

Resnick, Kimberly ;

Fusco, Nancy ;

Adams, Ramon ;

Redline, Raymond ;

Faulhaber, Peter ;

Dowlati, Afshin .

GYNECOLOGIC ONCOLOGY, 2013, 130 (01) :75-80

[34] Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers [J].

Kunos, Charles A. ;

Radivoyevitch, Tomas ;

Pink, John ;

Chiu, Song-Mao ;

Stefan, Tammy ;

Jacobberger, James ;

Kinsella, Timothy J. .

RADIATION RESEARCH, 2010, 174 (05) :574-581

[35] Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC # 663249) for Locally Advanced Cervical Cancer [J].

Kunos, Charles A. ;

Waggoner, Steven ;

von Gruenigen, Vivian ;

Eldermire, Elisa ;

Pink, John ;

Dowlati, Afshin ;

Kinsella, Timothy J. .

CLINICAL CANCER RESEARCH, 2010, 16 (04) :1298-1306

[36] Modulating Radiation Resistance by Inhibiting Ribonucleotide Reductase in Cancers with Virally or Mutationally Silenced p53 Protein [J].

Kunos, Charles A. ;

Chiu, Song-mao ;

Pink, John ;

Kinsella, Timothy J. .

RADIATION RESEARCH, 2009, 172 (06) :666-676

[37] A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer A Study of the PMH Phase II Consortium [J].

Leighl, Natasha B. ;

Laurie, Scott A. ;

Chen, Xueyu E. ;

Ellis, Peter ;

Shepherd, Frances A. ;

Knox, Jennifer J. ;

Goss, Glenwood ;

Burkes, Ronald L. ;

Pond, Gregory R. ;

Dick, Christopher ;

Yun, Yun ;

Zwiebel, James A. ;

Moore, Malcolm J. .

JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) :1163-1169

[38] Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640 [J].

Lewis, Clayton S. ;

Voelkel-Johnson, Christina ;

Smith, Charles D. .

ONCOTARGET, 2016, 7 (37) :60181-60192

[39] MicroRNA-4500 Inhibits Migration, Invasion, and Angiogenesis of Breast Cancer Cells via RRM2-Dependent MAPK Signaling Pathway [J].

Li, Shaoying ;

Mai, Huifen ;

Zhu, Yefeng ;

Li, Guofeng ;

Sun, Jing ;

Li, Guisen ;

Liang, Bichan ;

Chen, Shaojun .

MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 21 :278-289

[40]

Li Z.N., 2020, BIOCH BIOPHYS RES CO

← 1 2 3 4 5 6 7 8 9 10 →